FDA Approves Gamunex for Primary Humoral Immunodeficiency and Idiopathic Thrombocytopenic Purpura
Gamunex (immune globulin intravenous (human)) is indicated for the treatment of primary humoral immunodeficiency and idiopathic thrombocytopenic purpura.Posted: August 2003
Related articles
- FDA Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurological Disorder CIDP in the United States - September 15, 2008
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
